Home » Topics » BioWorld Science

BioWorld Science
RSS

Heparegenix identifies new MAPKK 4 inhibitors

Aug. 9, 2021

Discovery and preclinical characterization of a novel anti-SARS-CoV-2 MAb, MW-06

Aug. 9, 2021

Enrollment ongoing in first-in-human study of [68Ga]-FF58

Aug. 6, 2021

GI Innovation begins patient enrollment in phase I/II study of GI-101

Aug. 6, 2021

Labile iron pool radiotracer [18F]TRX can predict sensitivity to iron-targeted tumor therapies

Aug. 6, 2021

Boehringer Ingelheim initiates phase I/II study of BI-765128 in diabetic macular ischemia

Aug. 6, 2021

Enrollment starts in phase I study of ZYIL-1

Aug. 6, 2021

FDA places partial clinical hold on Aprea's myeloid malignancy programs

Aug. 6, 2021

Dosing begins in phase II portion of phase I/II trial of AKS-452

Aug. 6, 2021

Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria

Aug. 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...